TY - JOUR
T1 - Exosomal miRNAs in central nervous system diseases
T2 - biomarkers, pathological mediators, protective factors and therapeutic agents
AU - Xia, Xiaohuan
AU - Wang, Yi
AU - Huang, Yunlong
AU - Zhang, Han
AU - Lu, Hongfang
AU - Zheng, Jialin C.
N1 - Funding Information:
This work was supported in part by research grants from the State Key Program of the National Natural Science Foundation of China (No. 81830037 to JZ), the National Basic Research Program of China (973 Program Grant No. 2014CB965001 to JZ), Innovative Research Groups of the National Natural Science Foundation of China (# 81221001 to JZ), the Joint Research Fund for Overseas Chinese , Hong Kong and Macao Young Scientists of the National Natural Science Foundation of China (# 81329002 to JZ), the National Institutes of Health : 1R01NS097195-01 (JZ), Shanghai Sailing Program (No. 19YF1451700 to XX), and China Postdoctoral Science Foundation Grant (No. 2018M642087 to XX). We thank Justin Peer, Jie Zhu, Yanyan Zhang, and Dr. Ling Ye for proofreading the manuscript.
Publisher Copyright:
© 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Exosomes are small bilipid layer-enclosed extracellular vesicles that can be found in tissues and biological fluids. As a key cell-to-cell and distant communication mediator, exosomes are involved in various central nervous system (CNS) diseases, potentially through transferring their contents such as proteins, lipids and nucleic acids to the target cells. Exosomal miRNAs, which are small non-coding RNAs in the exosomes, are known to be more stable than free miRNAs and therefore have lasting effects on disease-related gene expressions. There are distinct profiles of exosomal miRNAs in different types of CNS diseases even before the onset of irreversible neurological damages, indicating that exosomal miRNAs within tissues and biological fluids could serve as promising biomarkers. Emerging evidence has also demonstrated the pathological effects of several exosomal miRNAs in CNS diseases via specific modulation of disease-related factors. Moreover, exosomes carry therapeutically beneficial miRNAs across the blood-brain-barrier, which can be exploited as a powerful drug delivery tool to help alleviating multiple CNS diseases. In this review, we summarize the recent progress made in understanding the biological roles of exosomal miRNAs as potential diagnostic biomarkers, pathological regulators, and therapeutic targets/drugs for CNS diseases. A comprehensive discussion of the main concerns and challenges for the applications of exosomal miRNAs in the clinical setting is also provided.
AB - Exosomes are small bilipid layer-enclosed extracellular vesicles that can be found in tissues and biological fluids. As a key cell-to-cell and distant communication mediator, exosomes are involved in various central nervous system (CNS) diseases, potentially through transferring their contents such as proteins, lipids and nucleic acids to the target cells. Exosomal miRNAs, which are small non-coding RNAs in the exosomes, are known to be more stable than free miRNAs and therefore have lasting effects on disease-related gene expressions. There are distinct profiles of exosomal miRNAs in different types of CNS diseases even before the onset of irreversible neurological damages, indicating that exosomal miRNAs within tissues and biological fluids could serve as promising biomarkers. Emerging evidence has also demonstrated the pathological effects of several exosomal miRNAs in CNS diseases via specific modulation of disease-related factors. Moreover, exosomes carry therapeutically beneficial miRNAs across the blood-brain-barrier, which can be exploited as a powerful drug delivery tool to help alleviating multiple CNS diseases. In this review, we summarize the recent progress made in understanding the biological roles of exosomal miRNAs as potential diagnostic biomarkers, pathological regulators, and therapeutic targets/drugs for CNS diseases. A comprehensive discussion of the main concerns and challenges for the applications of exosomal miRNAs in the clinical setting is also provided.
UR - http://www.scopus.com/inward/record.url?scp=85072776033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072776033&partnerID=8YFLogxK
U2 - 10.1016/j.pneurobio.2019.101694
DO - 10.1016/j.pneurobio.2019.101694
M3 - Review article
C2 - 31542363
AN - SCOPUS:85072776033
SN - 0301-0082
VL - 183
JO - Progress in Neurobiology
JF - Progress in Neurobiology
M1 - 101694
ER -